Royalty Pharma (RPRX) Interest Coverage Ratio (2019 - 2026)
Royalty Pharma (RPRX) posted Interest Coverage Ratio of 2.52 for Q1 2026, down 75.33% sequentially from 10.21 in Q4 2025, and down 13.97% YoY from 2.93 in Q1 2025.
Royalty Pharma (RPRX) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Interest Coverage Ratio for 8 years, with the latest figure at 2.52 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 13.97% year-over-year to 2.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.1 (down 31.78% YoY) and the FY2025 annual result came in at 5.07, down 11.56% from the prior year.
- Interest Coverage Ratio slipped to 2.52 in Q1 2026 per RPRX's latest filing, from 10.21 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 20.96 in Q4 2023 and troughed at 1997.31 in Q4 2024.
- A 5-year average of 157.44 and a median of 1.31 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio slumped 22389.86% in 2022, then surged 737.19% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 727.99 in 2022, then jumped by 102.88% to 20.96 in 2023, then sank by 9627.47% to 1997.31 in 2024, then jumped by 100.51% to 10.21 in 2025, then slumped by 75.33% to 2.52 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 2.52, 10.21, and 5.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.61 |
| Mar 31, 2026 | 2.52 |
| Dec 31, 2025 | 10.21 |
| Sep 30, 2025 | 5.37 |
| Jun 30, 2025 | 1.18 |
| Mar 31, 2025 | 2.93 |
| Dec 31, 2024 | -1,997.31 |
| Sep 30, 2024 | 3.82 |
| Jun 30, 2024 | 1.31 |
| Mar 31, 2024 | -0.46 |
| Dec 31, 2023 | 20.96 |
| Sep 30, 2023 | 0.90 |
| Jun 30, 2023 | 1.43 |
| Mar 31, 2023 | 2.68 |
| Dec 31, 2022 | -727.99 |
| Sep 30, 2022 | -1.02 |
| Jun 30, 2022 | -1.95 |
| Mar 31, 2022 | -1.10 |
| Dec 31, 2021 | 3.27 |
| Sep 30, 2021 | -1.45 |